its early stage, patients with metastatic melanoma show very poor prognosis. Standard cytotoxic chemotherapy gives very low response rate and immunotherapy with ipilimumab or interferon α shows somewhat improved responses in approximately 10% of metastatic melanoma patients (Hodi et al., 2010) . More recently, based on the fact that about half of metastatic melanoma patients harbor BRAF V600E mutation, small-molecule inhibitors such as vemurafenib and trametinib targeting this driver mutation or its downstream regulatory factor in extracellular signalregulated kinase (ERK)/mitogen-activated protein kinase (MAPK) pathway have been developed and approved worldwide (Ranchon et al., 2015) . Unfortunately, treatments of chemotherapeutic or molecular targeted drugs as monotherapy exhibit only transient responses due to development of drug resistance which results in recurrence and further progression of tumor (Nazarian et al., 2010; Villanueva et al., 2010) .
Metformin is a biguanide derivative that has been wide-ly used as a first-line therapeutic drug for type II diabetes mellitus for over 50 years. Metformin decreases blood glucose levels by inhibiting gluconeogenesis in liver and increasing uptake and utilization of glucose by skeletal muscle (Shaw et al., 2005) . It also proved to be welltolerable drug with low cost for the treatment of diabetic patients. During last decade, several studies suggest that treatment of metformin in diabetic patients lowers cancer risk and reduces cancer incidence (Donadon et al., 2010; Kong et al., 2015; Tseng, 2018) . Preclinical studies revealed that metformin inhibits cell proliferation and tumor growth in various cancer cell lines including melanoma both in vitro and in vivo (Cerezo et al., 2013; Griss et al., 2015) . Clinical trials also showed promising results, in which metformin treatment in non-diabetic patients with various cancers decreases the expression of Ki-67, a marker of cell proliferation (Niraula et al., 2012; Joshua et al., 2014; Schuler et al., 2015) . In addition, metformin has been reported to inhibit cell invasion and metastasis in many cancer cells, including melanoma cells (Cerezo et al., 2013; He et al., 2018) .
The molecular mechanisms underlying antitumor effect of metformin have been demonstrated but revealed as a much more complex nature (Vancura et al., 2018) . The most well-known effect of metformin is the inhibition of complex I in the mitochondrial electron transport chain, which leads to increasing the intracellular AMP/ATP ratio.
The high AMP/ATP ratio in turn activates adenosine monophosphate activated protein kinase (AMPK), a heterotrimeric serine/threonine protein kinase which regulates the multiple signaling pathways involved in cancer cell proliferation, including the suppression of mammalian target of rapamycin (mTOR) pathway (Griss et al., 2015) .
Metformin-mediated AMPK activation and mTOR inhibition suppress cell proliferation through reducing phosphorylation of its major downstream targets, the 70 kDa ribosomal protein kinase S6 (p70S6K) and eukaryotic initiation factor 4E-binding protein1 (4E-BP1) (Shaw et al., 2005) .
Paclitaxel (Taxol) is a frontline chemotherapeutic drug with a strong antitumor activity and has been used clinically for many years as a monotherapy or combination with other anticancer agents to treat a number of types of cancer including melanoma (Kottschade et al., 2011) . Binding of paclitaxel to β-tubulin stabilizes the microtubule polymer and protects it from disassembly, which leads to immediate cell cycle arrest at the G2/M phase, followed by apoptotic cell death (Ganesh et al., 2007) . However, the response rate of paclitaxel monotherapy is very low with 10%-15% and serious side effects plus drug resistance are significant clinical problems to the application of this drug in melanoma (Hersh et al., 2010) . Several studies revealed that resistance to paclitaxel is associated with the activation of ERK/MAPK pathway and inhibition of this pathway selectively potentiates the paclitaxel-induced cell death in diverse cancer (McDaid and Horwitz, 2001; Gupta et al., 2014) . Considering that ERK/MAPK pathway is associated with the regulation of cell survival and proliferation and mutations of BRAF and NRAS are found in 60% and 20% in malignant melanoma respectively, activation of ERK/ MAPK pathway in response to paclitaxel could compromise the anticancer effect of this drug. Of note, several recent reports showed that paclitaxel enhances metastasis by inducing the migration and invasion of cancer cells (Volk-Draper et al., 2014; Li et al., 2016) .
Our previous report revealed that metformin suppresses ERK activation (Kim et al., 2018) , which provides a rational molecular basis for the combination therapy of metformin and paclitaxel. The aims of this study were to determine the combined effect of metformin and paclitaxel 
Cell viability assay
MTT assay was applied to measure cell viability as described previously (Lee et al., 2017) . Briefly, cells were 
Western blotting
Western blotting assays were carried out as previously described (Lee et al., 2017) . Primary antibodies included pERK1/2 (Tyr204), ERK1/2, cyclin D1, N-cadherin, se- 
Colony formation assay
Cells were plated in 6-well culture dishes at a density of 600 cells per well. After 24 hr, cells were treated with paclitaxel, metformin and their combination. Every three days, medium was changed with fresh medium containing the corresponding concentration of the drugs. Following 15-day treatment, cell colonies were washed with cold PBS and then fixed with ice-cold 100% methanol. Cells were stained with 0.1% crystal violet in 20% methanol for 10 min and pictures were taken with a digital camera (Olympus). 2B ). The DRI values were always above 1 at any combination of two drugs (Fig. 2C) .
Next, to explore the mechanisms underlying the synergistic growth inhibitory effect between paclitaxel and metformin, we characterized the effect of this drug combination on downstream regulatory proteins of cell signaling pathways involved in cell survival and proliferation using Western blot analysis. After 24 hr of treatment, the combi- Cells were treated with paclitaxel (T, 5 nM), metformin (M, 2 mM) and their combinations for 24 hr. The combination of both drugs caused synergistic decrease of pERK, p4E-BP1 and pp38. β-actin was used as a loading control.
vation of AMPK (Fig. 2D) .
Effect of paclitaxel and metformin on the expression of proteins involved in EMT
Since recent reports suggest that metformin blocks me- In contrast, paclitaxel increased the levels of fibronectin and integrin β3, while it did not significantly affect levels of SPARC, integrin αV and N-cadherin (Fig. 3) . Next, we explored changes in the levels of those EMT marker proteins to determine the effect of paclitaxel and metformin combination. Our results showed that paclitaxel potentiated the metformin-induced inhibition of SPARC and fibronectin while there were no obvious alteration in the levels of N-cadherin, integrin αV and integrin β3.
Metformin potentiates the inhibition of paclitaxelinduced colony formation
In the present study, we revealed that metformin synergistically inhibits the melanomal cell growth induced by paclitaxel. To extend these results into long-term effect of the combination treatment, we tried colony formation assay by culturing SK-MEL-28 melanoma cells for 15 days.
As shown in Fig. 4 , paclitaxel or metformin as a single agent led to a partial inhibition of colony formation, whereas the combination of both drugs potentiated the inhibitory effect on the formation and growth of cell colonies as compared to either agent alone. These results further support the synergistic growth inhibitory effect of paclitaxel and metformin in cell survival assay.
The new therapeutic approach is important to manage the metastatic melanoma which is resistant to existing chemotherapies. Although the recently developed molecular targeted drugs like dabrafenib and trametinib show very high response rate (about 60%) for patients with V600 The antidiabetic drug metformin proved to be welltolerable drug with safety profile and low cost. Metformin as monotherapy or combination therapy inhibits the growth and proliferation of melanoma cell in vitro and in xenograft model (Niehr et al., 2011; Vujic et al., 2014) .
Our previous reports showed that metformin exerts its antitumor activity via the suppression of ERK phosphorylation as well as mTOR signaling pathway (Lee et al., 2017; Kim et al., 2018) . We, therefore, hypothesized that the combination of paclitaxel and metformin might be an effective strategy for inhibition of cell survival and proliferation in melanoma.
The present study demonstrated the synergistic inhibi- Tx, paclitaxel; Metf, metformin.
led to almost complete suppression of p38 activity. p38
MAPK plays dual role as a regulator of cell death, and it can either mediate cell survival or cell death depending on not only the type of stimulus but also in a cell type specific manner (Koul et al., 2013) . In addition, most carcinoma cells have shown that the activity of ERK/MAPK and p38
MAPK pathways appears to be mutually exclusive; high level of p38 activity inhibits ERK activity through negative feedback and prevents tumorigenesis (Aguirre-Ghiso et al., 2004) . In melanoma, however, both pathways are simultaneously activated, because the negative loop from p38 to ERK is lost and melanoma cells are insensitive to ERK inhibition by p38. This high activity of p38 and ERK in melanoma is correlated with cell proliferation and migration in vivo (Estrada et al., 2008) . Therefore, simultaneous inhibition of ERK and p38 activities could be more 
